Identification | Back Directory | [Name]
2-Piperazineacetonitrile, 1-[(2E)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-propen-1-yl]-4-[5,6,7,8-tetrahydro-7-(8-methyl-1-naphthalenyl)-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-, (2S)- | [CAS]
2326522-16-9 | [Synonyms]
KRAS G12C inhibitor 39 2-Piperazineacetonitrile, 1-[(2E)-3-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2-propen-1-yl]-4-[5,6,7,8-tetrahydro-7-(8-methyl-1-naphthalenyl)-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-, (2S)- | [Molecular Formula]
C37H43N9O2 | [MOL File]
2326522-16-9.mol | [Molecular Weight]
645.8 |
Hazard Information | Back Directory | [Uses]
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494)[1]. | [References]
[1] James F. Blake, et al. Kras g12c inhibitors. Patent WO2019099524A1. |
|
|